Eli lilly stock price remains resilient despite currency

Eli Lilly stock price remains resilient despite currency headwinds in international markets. Hedging strategies in place minimize FX impact, keeping EPS forecasts stable through FY CHONGQING, CHINA - MAY 04: In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen, with the company's stock market performance and candlestick chart visible in the background, on May 4, 2025, in Chongqing, China. Hims & Hers is an American telehealth company that provides personalized healthcare products and services for mental health, dermatology, sexual wellness, and primary care through a direct-to-consumer platform. (Photo illustration by Cheng Xin/Getty Images) Eli Lilly & Co has witnessed significant sales activity from Lilly Endowment Inc , a major shareholder. The endowment sold 113,694 shares for $86,792,716, followed by additional sales of 215,822 shares for $177,289,555, 135,193 shares for $107,362,359, and 112,596 shares for $92,502,494. These massive transactions underscore the endowment’s strategic decision to reduce its stake in the pharmaceutical giant, potentially reallocating resources to other ventures or causes. Eli Lilly stock price could surpass $915 if upcoming obesity drug data confirms extended efficacy benchmarks. Sentiment is notably positive among hedge funds with overweight positions in the pharmas.